Dr. Jorge E. Cortes CML Chronic Myeloid Leukemia
''Jorge Cortes, MD, is deputy chair and professor of medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston Texas where he directs the CML Program.''
Extract from the site of iCMLf (International Chronic Myeloid Leukemia Foundation).
NEW! Recently, he has been named director of the Georgia Cancer Center at Augusta University.
About Dr. Cortes by MDAnderson Cancer center
Dr. Jorge Eduardo Cortes by Bloomberg
The 2018 iCMLf Goldman Prize is awarded to Professor Jorge Cortes
Extract from the site of iCMLf (International Chronic Myeloid Leukemia Foundation).
NEW! Recently, he has been named director of the Georgia Cancer Center at Augusta University.
About Dr. Cortes by MDAnderson Cancer center
Dr. Jorge Eduardo Cortes by Bloomberg
The 2018 iCMLf Goldman Prize is awarded to Professor Jorge Cortes
VIDEOS
Dr. Cortes Discusses TKI Cessation in CML
September 13, 2018, OncLiveTV
PACE Trial: Phase II trial of ponatinib in patients with chronic myeloid leukaemia (CML)
January16, 2018, ecancer
Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment
December 18, 2017, OBRoncology
Faster, Better, Safer—Getting CML Treatment Right
December 23, 2016, PeerView Oncology
Meet leukemia oncologist Jorge Cortes
October 25, 2017, MD Anderson Cancer Center
Mutation Analysis in Chronic Myeloid Leukemia
January 14, 2016, OncLive
Study Brings Positive Results For the Most Resistant Types of CML
December 11, 2012, Patient Power
An Expert Explains Positive News on CML VIDEO
June 27, 2012, Patient Power
Dr. Jorge Cortes Discusses the Ponatinib Ph+All and CML Evaluation (PACE) Trial
June 14, 2012, OncLive
Living with CML Long-Term: Side-Effects, Treatment Cessation and Better Testing
January 22, 2012, Patient Power
Living With CML - Side Effects and Symptom Management
January 11, 2012, Patient Power
A Closer Watch and Newer Options for Better Long-Term Results
December 29, 2011, Patient Power
New Help for More CML Patients: Dr. Jorge Cortes
December 20, 2010, Patient Power
Treatment of patients after first line therapy
December 2010, iCMLf
ASH2010 - The ponatinib, a molecule with many potential patients resistant
December 6, 2010, Médecine Plus
CML: The Current Landscape - an interview with Dr. Jorge Cortes
October 2010, The National CML Society (US)
ASCO 2010: New treatments for CML (bosutinib)
September 2010, cancerconnect
CML Treatment: Old Drug, New Name
December 18, 2009, ElsGlobalMedicalNews
Interview with Jorges Cortes at EHA "How long to leave patients on treatment?"
June 2008, EHA (European Hematology Association)
ARTICLES
13 physicians named America’s Top Doctors for 2019
March 29, 2019, Augusta University
Dr. Jorge Cortes - Renowned clinical investigator selected as director for the Georgia Cancer Center
February 27, 2019, Augusta University
FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017, OncLive
Dr. Jorge Cortes Joins Dr. Andre Goy and Dr. Sagar Lonial as Co-Chair for the Landmark Physicians’ Education Resource® International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
September 06, 2017, Business Wire
How I treat newly diagnosed chronic phase CML
August 16, 2012, Journal Blood
13 physicians named America’s Top Doctors for 2019
March 29, 2019, Augusta University
Dr. Jorge Cortes - Renowned clinical investigator selected as director for the Georgia Cancer Center
February 27, 2019, Augusta University
FDA Approves Bosutinib for Newly-Diagnosed Ph+ CML
December 19, 2017, OncLive
Dr. Jorge Cortes Joins Dr. Andre Goy and Dr. Sagar Lonial as Co-Chair for the Landmark Physicians’ Education Resource® International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma
September 06, 2017, Business Wire
How I treat newly diagnosed chronic phase CML
August 16, 2012, Journal Blood
